Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Inventiva ( (IVA) ) has shared an update.
Inventiva reported first-quarter 2026 financial information on May 26, 2026, showing cash and cash equivalents of €75.0 million and €121.5 million in short-term deposits as of March 31, 2026, down from year-end 2025, with the decline mainly driven by planned spending on its lanifibranor development program. The company, which recorded no revenue in the quarter, said its current cash, equivalents and deposits should fund operations until mid–first quarter 2027, and potentially to mid–third quarter 2027 if all Tranche 3 warrants from its 2024 structured financing are exercised, while investors now look ahead to key NATiV3 Phase 3 topline data expected in the fourth quarter of 2026 and a series of investor and scientific conference appearances in the coming months.
The most recent analyst rating on (IVA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
The score is primarily held down by weak financial performance (large and widening losses, persistent cash burn, and negative equity with rising debt). Offsetting this, the earnings call indicated solid clinical execution and a clear timeline to a pivotal readout with meaningful cash on hand, while technicals are modestly supportive but not strongly bullish; valuation remains constrained by ongoing losses.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company developing orally administered small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), a progressive chronic liver disease. Its lead candidate, lanifibranor, a novel pan-PPAR agonist, is being evaluated in the pivotal Phase 3 NATiV3 trial in adult MASH patients, and the company is listed on Euronext Paris and the Nasdaq Global Market under the ticker IVA.
Average Trading Volume: 329,032
Technical Sentiment Signal: Buy
Current Market Cap: $1.06B
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.